For many foreign-based life sciences companies, the need to establish a business presence in the United States is a vital but often complicated process. These companies often have excellent products that would sell well in the U.S. market. However, finding an efficient and cost effective way to gain FDA regulatory approval and product launch can be time consuming and expensive.

Traditionally, companies have created this capability on their own (requiring infrastructure) or identified the need for a commercialization partner (sharing costs and profits). BioPortUSA offers a new alternative to foreign-based life science companies that have made the decision to enter the U.S. market.

The Market Landscape
For many companies, particularly those in Europe and Asia, entering the U.S. market is necessary to maximize their potential market capitalization. However, complex immigration, legal, tax or FDA regulatory issues often prevent companies from setting up entities in the United States. BioPortUSA offers these companies the benefits of partnering with U.S.-based professionals whose industry knowledge and market experience will ensure the successful establishment of a business entity and accelerate the commercialization of the product asset(s) in the U.S. market.

Compelling Reasons to Enter the U.S. Market
Life Sciences companies without a presence in the United States have difficulty competing with their U.S. sector counterparts at raising investor financing and maximizing the market valuation of their product asset(s) or of the business as a whole. For these firms the rationale for establishing a business entity/presence in the United States derives from financial, business development, operational, research & development, and commercial drivers, including:

• Largest healthcare market in the world ($ volume)
• Mature stock market (AMEX and NASDAQ specifically suitable for mid/small cap firms)
• Direct access to capital markets-to facilitate fund raising
• Wider potential base of investors
• Greater market capitalization potential
• Clinical trials/collaborations with U.S.-based research centers
• Greater commercialization partnering opportunities
• Higher visibility among stakeholders and scientific community

A Better Solution for Market Entry
Rather than trying to navigate U.S. market entry on their own, foreign-based companies can now take advantage of BioPortUSA’s coordinated services. Partnering with BioPortUSA will simplify the U.S. market entry process. By engaging BioPortUSA, client companies will be able to access a menu of core professional services all in one place that will enable them to correctly determine their early investment and accelerate the commercialization process for their product lines.